Check Cap (CHEK) Rating Increased to Buy at Zacks Investment Research

Check Cap (NASDAQ:CHEK) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Wednesday, March 7th. The firm currently has a $0.75 target price on the medical research company’s stock. Zacks Investment Research‘s target price indicates a potential upside of 7.47% from the stock’s current price.

According to Zacks, “Check Cap Ltd. is a medical diagnostics company. The company is engaged in the development of an ingestible imaging capsule for the screening of colorectal cancer. Check Cap Ltd. is based in Mount Carmel, Israel. “

Separately, HC Wainwright boosted their price objective on Check Cap from $5.50 to $6.00 and gave the stock a “buy” rating in a research report on Thursday, January 11th.

Check Cap (NASDAQ:CHEK) traded down $0.01 during trading on Wednesday, hitting $0.70. The stock had a trading volume of 182,135 shares, compared to its average volume of 289,059. Check Cap has a 12 month low of $0.60 and a 12 month high of $2.38. The firm has a market cap of $13.10, a PE ratio of -1.14 and a beta of -0.22.

An institutional investor recently bought a new position in Check Cap stock. Anson Funds Management LP purchased a new stake in Check Cap Ltd (NASDAQ:CHEK) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 332,302 shares of the medical research company’s stock, valued at approximately $289,000. Anson Funds Management LP owned about 1.73% of Check Cap at the end of the most recent quarter. Hedge funds and other institutional investors own 22.18% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Check Cap (CHEK) Rating Increased to Buy at Zacks Investment Research” was published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this news story on another website, it was stolen and republished in violation of U.S. and international trademark and copyright legislation. The legal version of this news story can be read at

Check Cap Company Profile

Check-Cap Ltd. (Check-Cap) is a clinical-stage medical diagnostics company. The Company is engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The Company’s system consists of main components, such as ingestible scanning capsule; Capsule Positioning System (CPS), a recorder worn on the patient’s back, and a personal computer (PC)-based work station for data reconstruction and image processing.

Get a free copy of the Zacks research report on Check Cap (CHEK)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Check Cap Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Check Cap and related companies with's FREE daily email newsletter.

Leave a Reply